Search Menu

Home
HTB
2017
August
01

1 August 2017

Contents

Hepatitis coinfection

FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US

HTB RSS

Early access

UK study for people with triple-class drug resistance 25 February 2021
VRC01 antibody only prevents minority of HIV infections: AMP study results 25 February 2021
Promising data for multipurpose technologies to prevent HIV and pregnancy 24 February 2021
Community murals in Soweto on dolutegravir-based ART: an i-Base collaboration 22 February 2021
All early access reports

Current issues

February 2021
January 2021
December 2020
Back issues

Special report

Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage

Home

i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links: HIV positive; Advocate; Professional; Donate; Feedback

Advice and information: Q and A; Phoneline; Pocket info; Guides; HIV meds; Glossary

Research and conference reports: HTB; HTB South; Pipeline report

Publications and resources: Publications; Other resources; Translations; Slide sets; Order and subscribe

News and updates: News; Blogs

Advocates' network: UK-CAB; Training manual

i-Base: About us; Contact; Sitemap; Home

Find us on Facebook